3 ms·
Their negotiating position is probably limited by the fact they can't say that they just won't buy it. NICE evaluates all treatments bought by the NHS for value
by ascorbic 10y ago
Their negotiating position is probably limited by the fact they can't say that they just won't buy it. NICE evaluates all treatments bought by the NHS for value for money. If it was too expensive they'd just not buy it. It's not like there are no alternatives.
- vonmoltke 10y agoActually, the big problem in the US is that there are no alternatives. The last Mylan competitor making a similar product folded six months ago. If you want to blame anything about the US system for the current situation, blame the regulatory capture that is generic drug approval. What does the NHS do about drugs that are sole source?